SCONE Therapy for Neurogenic Bladder
(CONTINENCE Trial)
Recruiting in Palo Alto (17 mi)
+13 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: SpineX Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial is testing a treatment called SCONE neuromodulation therapy, which uses electrical or magnetic signals to help nerves work better. It aims to improve bladder problems in people whose bladder issues are caused by nerve problems. The study will compare this treatment to another to see if it is safe and effective. SCONE™ therapy represents the first of its kind therapy to treat symptoms of urgency, frequency, and urge urinary incontinence in patients with OAB.
Eligibility Criteria
This trial is for adults aged 18-70 (75 for females) with stable medical conditions and a support network. They must have neurogenic lower urinary tract dysfunction due to spinal cord injury, multiple sclerosis, or stroke, and be at least one year post-diagnosis. Participants need symptoms like urgency or frequent urination/incontinence and no significant autonomic dysreflexia, severe heart/kidney/liver disease, other CNS diseases besides the qualifying ones, morphologic bladder obstruction history, or reliance on indwelling catheters.Inclusion Criteria
Your score on the NBSS survey is higher than 28.
I understand the study, agree to participate, and have signed the consent form.
I often feel a strong need to urinate or need to use the bathroom more than once every 2 hours.
See 11 more
Exclusion Criteria
I have had a bladder botox injection in the last year.
Subject is pregnant or trying to become pregnant; or is nursing.
Subject is known or suspected to be non compliant; and/or subject is unable or unwilling to comply with study requirements.
See 19 more
Treatment Details
Interventions
- SCONE (Neuromodulation)
Trial OverviewThe SCONE 'CONTINENCE' study tests if SCONE neuromodulation therapy can improve symptoms of Neurogenic Lower Urinary Tract Dysfunction after 12 weeks compared to a sham control. It's designed to see how effective and safe this treatment is in managing issues like urinary urgency and incontinence.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Therapeutic ArmExperimental Treatment1 Intervention
Group II: Sham ArmPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Atrium HealthCharlotte, NC
Mayo Clinic, St. Mary's CampusRochester, MN
University of Miami, Desai Sehti Urology InstituteMiami, FL
Medstar National RehabWashington DC, United States
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
SpineX Inc.Lead Sponsor
Craig Hospital, Englewood, Colorado, United StatesCollaborator
University of Miami, Miami, United StatesCollaborator
Shepherd Center, Atlanta, Georgia, United StatesCollaborator
Mayo Clinic, Rochester, Minnesota, United StatesCollaborator
MedStar National Rehabilitation Network, Washington, District of Columbia, United StatesCollaborator
Institute of Brain and Spine (IBS Hospital), New Delhi, IndiaCollaborator
Rancho Los Amigos National Rehabilitation Center, Downey, California, United StatesCollaborator
Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United StatesCollaborator
University of California, San Diego, California United StatesCollaborator